题目内容

In March 2017, Yescarta (axicabtagene ciloleucel), a ________-directed genetically modified autologous T cell immunotherapy, was approved by FDA.

A. CD15
B. CD19
CD29
D. CD44

查看答案

搜索结果不匹配？点我反馈

更多问题

On August 30, 2017, the US FDA approved Kymriah (tisagenlecleucel, Novartis)for the treatment of patients aged ≤25 years with B-cell precursor ______________________ that is refractory, in second relapse, or later relapse.

A. acute myelogenous (or myeloid) leukemia (AML)
B. acute lymphocytic (or lymphoblastic) leukemia (ALL)
C. chronic myelogenous (or myeloid) leukemia (CML)
D. chronic lymphocytic (or lymphoblastic) leukemia (CLL)

查看答案

On 24 May 2019, Zolgensma (onasemnogene abeparvovec-xioi, AVXS-101) was approved by the FDA indicated for the treatment of pediatric patients less than ___ years of age with spinal muscular atrophy (SMA) with biallelic mutations in the survival motor neuron 1 (SMN1) gene.

A. 1
B. 2
C. 3
D. 5

查看答案

_____________ is the first therapeutic treatment approved to treat the rare and fatal spinal muscular atrophy (SMA) disease. SMA is a severe neuromuscular disease that causes extreme muscle weakness and paralysis caused by a genetic defect in the SMN1 gene.

A. Luxturna
B. Kymriah
C. Zolgensma
D. Yescarta

查看答案

Spinal muscular atrophy (SMA)is diagnosed in approximately one out of every _________ live births and is the leading genetic cause of infant mortality.

A. 8,000
B. 10,000
C. 12,000
D. 15,000

查看答案

In March 2017, Yescarta (axicabtagene ciloleucel), a ________-directed genetically modified autologous T cell immunotherapy, was approved by FDA.

A. CD15 B. CD19 CD29 D. CD44

On August 30, 2017, the US FDA approved Kymriah (tisagenlecleucel, Novartis)for the treatment of patients aged ≤25 years with B-cell precursor ______________________ that is refractory, in second relapse, or later relapse.

On 24 May 2019, Zolgensma (onasemnogene abeparvovec-xioi, AVXS-101) was approved by the FDA indicated for the treatment of pediatric patients less than ___ years of age with spinal muscular atrophy (SMA) with biallelic mutations in the survival motor neuron 1 (SMN1) gene.

_____________ is the first therapeutic treatment approved to treat the rare and fatal spinal muscular atrophy (SMA) disease. SMA is a severe neuromuscular disease that causes extreme muscle weakness and paralysis caused by a genetic defect in the SMN1 gene.

Spinal muscular atrophy (SMA)is diagnosed in approximately one out of every _________ live births and is the leading genetic cause of infant mortality.

A. CD15
B. CD19
CD29
D. CD44